Market capitalization | $39.83m |
Enterprise Value | $-30.28m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.01 |
EV/Sales (TTM) EV/Sales | -61.80 |
P/S ratio (TTM) P/S ratio | 81.29 |
P/B ratio (TTM) P/B ratio | 0.63 |
Revenue growth (TTM) Revenue growth | 39.27% |
Revenue (TTM) Revenue | $490.00k |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
3 Analysts have issued a VYNE Therapeutics Inc forecast:
3 Analysts have issued a VYNE Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.49 0.49 |
40%
40%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -38 -38 |
23%
23%
|
EBIT (Operating Income) EBIT | -38 -38 |
24%
24%
|
Net Profit | -34 -34 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercialize solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company is headquartered in Bridgewater, NJ.
Head office | United States |
CEO | David Domzalski |
Employees | 10 |
Founded | 2011 |
Website | www.vynetherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.